Ovarian Cancer Clinical Trial
Official title:
Open Label Randomized Clinical Study of Plasmid Encoding p62/SQSTM1 (ELenagen) in in Combination With Gemcitabine in Patients With Platinum-resistant Ovarian Cancer
Verified date | July 2023 |
Source | CureLab Oncology |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
Phase II, two arm prospective study of efficacy and safety of ELENAGEN in combination with gemcitabine in comparison with gemcitabine alone in patients with platinum-resistant ovarian cancer.
Status | Active, not recruiting |
Enrollment | 40 |
Est. completion date | December 30, 2024 |
Est. primary completion date | December 30, 2024 |
Accepts healthy volunteers | No |
Gender | Female |
Age group | 18 Years to 70 Years |
Eligibility | Inclusion Criteria: - The patient is 18-70 years old. - Written informed consent of the patient to participate in clinical trials. - Presence of histologically confirmed ovarian cancer. - The return of the disease occurred less than 6 months after the last administration of platinum. - Presence of measurable tumor lesions according to RECIST 1.1 criteria. - Functional status according to ECOG scale is 0-2. - Life expectancy of at least 6 months. - Adequate function of the organs as determined by the following criteria: 1. Absolute number of neutrophils (ANN) =1500/mm3 (=1.5 × 109/l); 2. Platelet count =100,000/mm3 (IU: =100 × 109/l). 3. Hemoglobin level = 9.0 g/dL determined by analysis performed at least 2 weeks after the last hemotransfusion; 4. The level of AST and ALT in blood serum not exceeding more than 3 times the upper limit of the norm. 5. The level of serum bilirubin not exceeding more than 1.5 times the upper limit of normal. 6. Serum Creatinine = 1.5 mg/dL. - The ability of the patient to follow the directions of the research physician and follow the study regimen. Exclusion Criteria: Criteria by which patients are not included in the study - Platinum-sensitive relapse of ovarian cancer (disease recurrence occurred more than 6 months after the last administration of platinum drugs). - Presence of serious diseases or health conditions: 1. Other malignancies, with the exception of malignancies treated more than 5 years ago without signs of return of the disease. 2. Brain metastases or leptomeningeal metastases. 3. Active infection (e.g. fever =38 °C), including active or unresolved pneumonia/pneumonitis. 4. Uncontrolled diabetes mellitus. 5. Myocardial Infarction in the last 12 months, severe/unstable angina, clinically manifested heart failure class III-IV according to the classification of the New York Cardiology Association (NYCA). 6. Gastrointestinal bleeding within the last 2 weeks. 7. Human immunodeficiency virus (HIV), chronic or acute hepatitis B or hepatitis C. 8. Patients with autoimmune disorders or organ transplantation who require immunosuppressive therapy. I. Mental illness that may increase the risk associated with participation in the study or taking the study drug or that may affect the interpretation of the results of the study. K. Polyallergy, bronchial asthma (including aspirin) in history. - Major surgery during the previous 4 weeks (complete wound healing). - Previous chemotherapeutic treatment of the patient according to the scheme GEMCITABINE - Radiotherapy with extended field radiation within the previous 4 weeks or radiotherapy with a limited field radiation within the previous 2 weeks. |
Country | Name | City | State |
---|---|---|---|
Belarus | Minsk City Clinical Oncology Center | Minsk |
Lead Sponsor | Collaborator |
---|---|
CureLab Oncology |
Belarus,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Progression-free survival (PFS) | Median duration of time from start of treatment to time of progression by RESIST 1.1 criterion or death | 2 years since the start of treatment | |
Secondary | Safety of Elenagen in combination with Gemcitabine | Frequency of drug-related adverse events (AEs) and serious AEs (SAEs) according to NCI CTCAE version 5.0. | 1 year after the start of treatment |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT02526017 -
Study of Cabiralizumab in Combination With Nivolumab in Patients With Selected Advanced Cancers
|
Phase 1 | |
Withdrawn |
NCT05201001 -
APX005M in Patients With Recurrent Ovarian Cancer
|
Phase 2 | |
Completed |
NCT02963831 -
A Study to Investigate ONCOS-102 in Combination With Durvalumab in Subjects With Advanced Peritoneal Malignancies
|
Phase 1/Phase 2 | |
Not yet recruiting |
NCT06376253 -
A Phase I Study of [177Lu]Lu-EVS459 in Patients With Ovarian and Lung Cancers
|
Phase 1 | |
Recruiting |
NCT05489211 -
Study of Dato-Dxd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03)
|
Phase 2 | |
Recruiting |
NCT03412877 -
Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in People With Metastatic Cancer
|
Phase 2 | |
Active, not recruiting |
NCT03667716 -
COM701 (an Inhibitor of PVRIG) in Subjects With Advanced Solid Tumors.
|
Phase 1 | |
Active, not recruiting |
NCT03170960 -
Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors
|
Phase 1/Phase 2 | |
Recruiting |
NCT05156892 -
Tamoxifen and SUBA-Itraconzole Combination Testing in Ovarian Cancer
|
Phase 1 | |
Suspended |
NCT02432378 -
Intensive Locoregional Chemoimmunotherapy for Recurrent Ovarian Cancer Plus Intranodal DC Vaccines
|
Phase 1/Phase 2 | |
Recruiting |
NCT04533763 -
Living WELL: A Web-Based Program for Ovarian Cancer Survivors
|
N/A | |
Active, not recruiting |
NCT03371693 -
Cytoreductive Surgery(CRS) Plus Hyperthermic Intraperitoneal Chemotherapy(HIPEC) With Lobaplatin in Advanced and Recurrent Epithelial Ovarian Cancer
|
Phase 3 | |
Withdrawn |
NCT03032614 -
Combination of Carboplatin, Eribulin and Veliparib in Stage IV Cancer Patients
|
Phase 2 | |
Completed |
NCT01936363 -
Trial of Pimasertib With SAR245409 or Placebo in Ovarian Cancer
|
Phase 2 | |
Completed |
NCT02019524 -
Phase Ib Trial of Two Folate Binding Protein Peptide Vaccines (E39 and J65) in Breast and Ovarian Cancer Patients
|
Phase 1 | |
Terminated |
NCT00788125 -
Dasatinib, Ifosfamide, Carboplatin, and Etoposide in Treating Young Patients With Metastatic or Recurrent Malignant Solid Tumors
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT05059522 -
Continued Access Study for Participants Deriving Benefit in Pfizer-Sponsored Avelumab Parent Studies That Are Closing
|
Phase 3 | |
Active, not recruiting |
NCT04383210 -
Study of Seribantumab in Adult Patients With NRG1 Gene Fusion Positive Advanced Solid Tumors
|
Phase 2 | |
Terminated |
NCT04586335 -
Study of CYH33 in Combination With Olaparib an Oral PARP Inhibitor in Patients With Advanced Solid Tumors.
|
Phase 1 | |
Terminated |
NCT03146663 -
NUC-1031 in Patients With Platinum-Resistant Ovarian Cancer
|
Phase 2 |